Title:

Evaluation of the Antipruritic Effects of Topical Pimecrolimus in Non-Atopic Prurigo Nodularis: Results of a Randomized,...



Authors: Thomas Anton LugerMatthias AugustinSonja StänderChristine BlomeTrude Butterfass‐BahloulNgoc Quan PhanDorothee SiepmannTobias LottsMatthias Braeutigam
Year: 2013
Times cited: 31

Key People For Topical Pimecrolimus

Top KOLs in the world
#1
Thomas ***** *****
atopic dermatitis chronic pruritus pimecrolimus cream
#2
Carle * *****
atopic dermatitis psoriatic arthritis psoriasis patients
#3
Josef ********* ***********
asm 981 palisade endings human skin
#4
Jean **** *******
epidermolysis bullosa atopic dermatitis melanoma cells
#5
Anton ******
atopic dermatitis pimecrolimus tacrolimus calcineurin inhibitors
#6
Thomas *******
atopic dermatitis pimecrolimus cream topical corticosteroids

Evaluation of the Antipruritic Effects of Topical Pimecrolimus in Non-Atopic Prurigo Nodularis: Results of a Randomized, Hydrocortisone-Controlled, Double-Blind Phase II Trial

Abstract

BACKGROUND: In the treatment of atopic dermatitis, pimecrolimus has high antipruritic effects.

OBJECTIVE: To investigate the efficacy of 1% pimecrolimus cream in comparison to 1% hydrocortisone cream in non-atopic prurigo nodularis (PN).

METHODS: A randomized, controlled, double-blind study with intraindividual randomization was done in 30 patients (17 females, 13 males; mean age 58.5 years) with PN.

RESULTS: Pruritus intensity decreased significantly (p < 0.001) on both treated sides as early as after 10 days of treatment; scratch lesions improved (p < 0.001). Quality of life as assessed by the Dermatology Life Quality Index improved significantly. However, a significant advantage of pimecrolimus over hydrocortisone was not found.

CONCLUSION: The results suggest that the non-steroid pimecrolimus is an effective alternative for PN treatment.

Sign-in to see all concepts, it's free!